drugset / Trial / NCT02856126

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

NCT02856126

Phase 3 Completed 214 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with BCLC stage hepatocellular carcinoma (HCC).

Timeline

Start
2016-08
Primary completion
2020-10
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator EADM Unknown Other
Subject Leucovorin Small molecule Other
Comparator Lobaplatin Small molecule Other
Comparator MMC Unknown Other
Subject Oxaliplatin Small molecule Other
Subject fluorouracil Small molecule Other
Background Sorafenib Small molecule 400 mg Oral